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Kalpaj Parekh, MD,a Harold M. Burkhart, MD,a Ammar Hatab, MD,b Alan Ross, MD,c and Barbara A. Muller, MD,b
Iowa City, Iowa
Heparin remains the drug of choice required for anti-coagulation during cardiopulmonary bypass. Advan-tages of heparin over other drugs are its rapid onset ofaction after intravenous administration and its rapid
reversibility with protamine. Heparin-induced anaphylaxis, although
rare, has been reported.1 We report successful desensitization to
heparin in a patient requiring pulmonary valve replacement.
Clinical Summary
A 55-year-old woman with a history of a tetralogy of Fallot repair
done at age 10 years presented with congestive heart failure. Trans-
esophageal echocardiography and cardiac catheterization revealed
free pulmonary valve insufficiency requiring replacement. The med-
ical history was significant for heparin allergy first observed at the
time of the original cardiac surgery in 1959. She had generalized
hives and itching immediately after surgical intervention that was
thought to be attributable to heparin infusion. In 1970, she expe-
rienced pulmonary embolism and was re-exposed to intravenous
heparin, triggering immediate onset of generalized hives, itching,
and chest tightness. Over the years, routine intravenous line flushes
triggered localized self-limited urticaria and pruritus extending up
the arm. Our preoperative evaluation uncovered a convincing
history for heparin allergy that was thought to be anaphylactoid in
nature on the basis of existing literature and the lack of a defined,
pathophysiologic, immunoglobulin E (IgE)–mediated mechanism.
In the absence of a standardized skin test for heparin hypersensi-
tivity, the options available were to either desensitize to heparin or
use an alternate anticoagulant. In view of the anticipated reopera-
tive operation, it was decided to perform cautious intravenous
desensitization as the optimal strategy to decrease the potential risk
for significant side effects.
Al-Eryani and colleagues2 reported heparin desensitization
before cardiopulmonary bypass by gradually increasing the
dose of heparin intravenously, starting with 100 U in 1 L of
saline over 24 hours. We adapted their dosing protocol by
premedicating with acetaminophen (INN: paracetamol) and di-
phenhydramine (Benadryl, Pfizer) and keeping intramuscular
(0.3 mL, 1:1000 concentration) epinephrine available at the
bedside. When the infusion containing 100 U of heparin in 1000
mL of saline was started, she experienced generalized itching,
shortness of breath, diarrhea, and chest tightness within 10
minutes. The infusion was stopped, and intramuscular epineph-
rine and an oral H1 antagonist were administered, which alle-
viated the symptoms. On the following day, 10 U of heparin in
1000 mL of saline was infused over 24 hours. The patient
tolerated the heparin concentration well, without allergic side
effects. The heparin concentration was subsequently increased
to 100 U of heparin in 1000 mL of saline and infused over the
next 24 hours, which was well tolerated. On day 3, the 24-hour
infusion consisted of 1000 U of heparin, and on day 4, 5000 U
of heparin was infused. By the fifth day, the patient was
tolerating 500 U/h of heparin. On the sixth day, the heparin
infusion was temporarily reduced to 100 U/h to accommodate
intraoperative monitoring catheters. Full heparinization was
initiated with cardiopulmonary bypass, and pulmonary valve
replacement was performed successfully with a No. 29 Mosaic
valve (Medtronic, Inc, Minneapolis, Minn). The postoperative
course was uneventful, and she was discharged on postoperative
day 5. Table 1 depicts the heparin desensitization protocol used
preoperatively.
Discussion
Heparin-induced IgE-mediated hypersensitivity and anaphylac-
toid reactions, although rare, can pose a serious clinical prob-
lem for patients requiring cardiopulmonary bypass.3 Standard-
ized skin tests with heparin components are not available to
investigate for IgE-mediated heparin allergy, nor are they as
reliable as standard penicillin skin tests with major and minor
determinant components of the penicillin molecule. Typically,
the most commonly encountered adverse reactions to heparin
are hemorrhage, delayed hypersensitivity reactions, and hepa-
rin-induced thrombocytopenia (HIT). HIT is an autoimmune-
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TABLE 1. Protocol for heparin desensitization
Day 1 10 U of heparin in 1000 mL of saline at 42 mL/h
for 24 h
Day 2 100 U of heparin in 1000 mL of saline at 42 mL/h
for 24 h
Day 3 1000 U of heparin in 1000 mL of saline at 42 mL/h
for 24 h
Day 4 5000 U of heparin in 1000 mL of saline at 42 mL/h
for 24 h
Day 5 500 U of heparin per h for 24 h
Day 6 100 U/h 3 hours before initiating cardiopulmonary
bypass
Adapted with permission from al-Eryani and colleagues.2
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mediated reaction whereby IgG and IgM antibodies are directed
against heparin and platelet factor.4 Desensitization is not a
therapeutic option for acute or delayed HIT. Cases have been
reported in which alternative drugs, such as bovine heparin,
ancrod, and argatroban, have been used in place of heparin
when anaphylactoid reactions are suspected; however, their
efficacy has been anecdotal and needs further investigation.4
Two reports exist in the literature in which desensitization
for heparin allergy was attempted before cardiopulmonary by-
pass.2,5 Until more experience is gained with the use of alter-
native anticoagulation agents for cardiopulmonary bypass, we
advocate the use of heparin desensitization as successfully
performed in this case.
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Surgical treatment of recurrent transient ischemic
attacks and hemoptysis in a young man with
multiple pulmonary arteriovenous malformations
Cliff K. Choong, FRACS,a Daniel M. Goodenberger, MD,b,c Daniel Picus, MD,b,d and
Bryan F. Meyers, MD,a St Louis, Mo
Pulmonary arteriovenous malformation (PAVM) is a rarevascular anomaly with an incidence of 2 to 3 per 100,000population.1 We present a patient whose therapy withembolotherapy for PAVMs resulted in recurrent tran-
sient ischemic attacks (TIAs) and massive hemoptysis requiring
treatment by surgical resection.
Clinical Summary
A 17-year-old man with hereditary hemorrhagic telangiectasia
(HHT) had PAVMs incidentally discovered on a chest x-ray film.
Investigations confirmed PAVMs without the presence of associ-
ated bronchial collateral artery. Although his pulse oxygen satu-
ration at rest was 80%, he was asymptomatic. He underwent
embolization therapy with aneurysmal coil placement and cyano-
acrylate glue elsewhere (Figures 1A and 1B). One week later, he
had the first of recurrent TIAs with tingling and numbness in the
right upper extremity. Inves-
tigations including carotid du-
plex scan, echocardiography,
and cerebral CT and MRI did
not reveal any abnormalities. The TIAs were considered to be most
likely caused by emboli originating from clot propagation distal to
the coils. Six months later, he had the first of multiple episodes of
hemoptysis of 16 ounces or more, which were unresponsive to
embolotherapy of several smaller PAVMs. Angiography at our
center showed occlusion of the majority of the PAVMs. A large
bronchial artery was however seen, supplying an area of neovas-
cularization of the inflammatory complex of cyanoacrylate in the
apical segment of the right lower lobe, with rapid filling of the
pulmonary vein, implying arteriovenous shunting (Figure 2A). The
vessel was larger than the largest Ivalon particles, and an attempt
to occlude it by embolotherapy was considered to be potentially
hazardous and unlikely to result in a lasting occlusive effect. A
decision was made to remove the large PAVMs of the right lower
lobe by surgical resection. He underwent an uneventful right lower
lobectomy and at 1-year follow-up, he remained well with no
further TIA or hemoptysis. A transverse section of the resected
lung with coils in the PAVM is shown in Figure 2B.
Discussion
PAVM was first reported in 1897 by Churton in a 12-year-old boy
who had episodes of epistaxis, hemoptysis, and loud pulmonary
systolic bruit.2 At postmortem examination, he was found to have
multiple bilateral PAVMs. More than 80% of PAVMs are con-
genital in origin, and of these 60% to 90% are associated with
HHT.1 Conversely, 15% to 35% of the population with HHT have
a PAVM. The rate of PAVM in our 292 HHT patients was 58%.
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